Company / Capital Expenditures
Dianthus Therapeutics, Inc. /DE/ Capital Expenditures History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$110.0K
FY2024
5-year range
$110.0K / $1.3M
FY2020-FY2024
Trend
+0.0%
vs FY2023
Sector context
#168 of 194
Health Care
What the data says
Dianthus Therapeutics, Inc. /DE/'s capital expenditures of $110,000 is lower than 87% of companies in the Health Care sector (FY2024). Capital Expenditures has fluctuated over the past 9 years, ranging from $110,000 in FY2024 to $8M in FY2018.
Based on SEC 10-K filings.
$110,000 in FY2024 with a 5-year CAGR of -48.6%.
Declined from $139,000 to $110,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -55.7%
- 5-Year CAGR
- -48.6%
- 10-Year CAGR
- -
Sector benchmark
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of -48.6%, indicating a declining trend.
- In FY2024, capital expenditures increased 0.0% year-over-year.
- Ranks #168 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.46 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $110.0K | +0.0% |
| FY2023 | $110.0K | -20.9% |
| FY2022 | $139.0K | -89.0% |
| FY2021 | $1.3M | +216.0% |
| FY2020 | $400.0K | -86.9% |
| FY2019 | $3.1M | -60.1% |
| FY2018 | $7.7M | +248.9% |
| FY2017 | $2.2M | +1482.0% |
| FY2016 | $139.0K | - |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026